Form 4: Vera Therapeutics CEO Boosts Equity Holdings

Vera Therapeutics' President and CEO, Marshall Fordyce, reported significant equity awards including restricted stock units and stock options, alongside a transfer of shares to a trust.

Summary

• Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (VERA), was granted 68,800 Restricted Stock Units (RSUs) on February 4, 2026, under the Issuer's 2021 Equity Incentive Plan.
• These RSUs will vest in four equal annual installments on February 20, 2027, 2028, 2029, and 2030, contingent on continuous service.
• Fordyce also received a stock option to purchase 137,500 shares of Class A Common Stock on February 4, 2026, with an exercise price of $42.74 and an expiration date of February 3, 2036.
• The stock option vests monthly over 48 months, with the first 1/48th vesting on March 4, 2026, subject to continuous service.
• On November 19, 2025, Fordyce transferred 99,081 shares of Class A Common Stock to The Fordyce Revocable Trust for no consideration, where he serves as a trustee.
• His direct beneficial ownership of Class A Common Stock is 274,088 shares, which includes 623 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2025.
• Indirect beneficial ownership includes 122,949 shares by GRAT and 99,081 shares by The Fordyce Revocable Trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting routine executive compensation that aligns management incentives with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of 68,800 Restricted Stock Units (RSUs) and options for 137,500 shares aligns the CEO's long-term incentives with shareholder interests, promoting sustained performance.
• The significant equity awards demonstrate continued commitment and confidence from the company in its top executive.

Future Outlook

The vesting schedules for the granted RSUs and stock options extend through February 2030 and February 2036, respectively, indicating a long-term commitment from the CEO to the company's future performance and growth, contingent on continuous service.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and stock options to executive leadership is a standard practice in the biotechnology and pharmaceutical industry. These equity awards are crucial for attracting, retaining, and motivating key executives, aligning their financial interests with the long-term success and shareholder value creation of the company. The vesting schedules typically span several years, reinforcing a focus on sustained performance.

Related Party Transactions

• On November 19, 2025, Marshall Fordyce transferred 99,081 shares of Class A Common Stock to The Fordyce Revocable Trust, an entity where he serves as a trustee.

Stakeholder Impact

• Shareholders: The equity awards align the CEO's financial interests with long-term shareholder value creation, potentially fostering greater commitment to company performance.
• Employees: The equity incentive plan and employee stock purchase plan mentioned indicate broader employee participation in company ownership, which can boost morale and retention.

Next Steps

• Continued vesting of 68,800 Restricted Stock Units annually through February 2030, subject to continuous service.
• Continued monthly vesting of stock options for 137,500 shares through February 2030, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing primarily details routine executive compensation grants and a personal estate planning transfer. While the grants align management's interests with shareholders, they do not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing fundamental analysis.

Keywords

Vera Therapeutics, VERA, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Incentive Plan, CEO Compensation, Corporate Governance